NCT00121745 - Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

July 31, 2007

Conditions

Pancreatic Cancer

Interventions

GENETIC

Rexin-G Dose 1

Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml

GENETIC

Rexin-G Dose 2

Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml

GENETIC

Rexin-G Dose 3

"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"

GENETIC

Rexin-G Dose 4

"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"

Trial Locations (1)

Mayo Clinic, Rochester